• 1
    Tannock IF,de Wit R,Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 15021512.
  • 2
    Kopetz ES,Nelson JB,Carducci MA. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs. 2002; 20: 173182.
  • 3
    Carducci MA,Saad F,Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007; 110: 19591966.
  • 4
    Nelson JB,Love W,Chin JL, et al. Phase 3, randomized controlled trial of atrasentan in patients with nonmetastatic hormone-refractory prostate cancer. Cancer. 2008; 113: 24782487.
  • 5
    Curwen JO,Wilson C. ZD4054: a specific endothelin A receptor antagonist with potential utility in prostate cancer and metastatic bone disease [abstract]. Eur J Cancer. 2002; 38: S102.
  • 6
    Dawson N,Phung D,Morris T, et al. Impact of the specific endothelial A receptor antagonist ZD4054 on overall survival and bone metastases in patients with hormone-resistant prostate cancer: results of a phase II trial [abstract]. Presented at the ASCO 2008 Genitourinary Cancers Symposium, San Francisco, California, February 14-16, 2008. Abstract 7.
  • 7
    Mohammad K,McKenna C,Mison A, et al. Combined endothelin A receptor antagonist and bisphosphonate treatment more effectively reduces prostate cancer growth in bone than either alone [abstract]. Presented at the American Society for Bone and Mineral Research 27th Annual Meeting, Nashville, Tennessee, September 23-27, 2005. Abstract 1213a.